ReviewCurrent cardiology reports2017
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 53 citations in OpenAlex.
- A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.Drug design, development and therapy · 2019Trial
- Plant sterols lower LDL-cholesterol and triglycerides in dyslipidemic individuals with or at risk of developing type 2 diabetes; a randomized, double-blind, placebo-controlled study.Nutrition & diabetes · 2018Trial
- Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Cardiovascular diabetology · 2017Trial
- Development and validation of a nomogram prediction model for coronary heart disease in diabetic patients: a study based on the 2011-2020 NHANES database.BMC cardiovascular disorders · 2025Article
- Association of remnant cholesterol with progression and regression of prediabetes in middle-aged and older adults: a nationwide cohort study.Acta diabetologica · 2025Article
- A predictive model to assess the risk of developing hyperlipidemia in patients with type 2 diabetes.PloS one · 2025Article
- Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition).Journal of translational internal medicine · 2024Article
- Therapeutic potential of herbal medicine for the management of hyperlipidemia: latest updates.Environmental science and pollution research international · 2022Review
- Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- A New Treatment Strategy for Diabetic Dyslipidemia?Diabetes · 2020Article
- Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials.Iranian journal of public health · 2019Review
- Ameliorative Effect and Mechanism of the Purified Anthraquinone-Glycoside Preparation fromMolecules (Basel, Switzerland) · 2019Article
- CYC27 Synthetic Derivative of Bromophenol from Red AlgaMarine drugs · 2019Article
- Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?Biochimica et biophysica acta. Molecular and cell biology of lipids · 2018Review
- Dyslipidaemia was correlated to the posterior circulation infarction in non-diabetic populations.Lipids in health and disease · 2018Article
- Stearate-to-palmitate ratio modulates endoplasmic reticulum stress and cell apoptosis in non-B non-C hepatoma cells.Cancer science · 2018Article
- Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.Proceedings (Baylor University. Medical Center) · 2018Review
- Transcriptome profile analysis of leg muscle tissues between slow- and fast-growing chickens.PloS one · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewCurrent preventive and treatment guidelines for type 2 diabetes have failed to decrease the incidence of comorbidities, such as dyslipidemia and ultimately heart disease. The goal of this review is to describe the physiological and metabolic lipid alterations that develop in patients with type 2 diabetes mellitus. Questions addressed include the differences in lipid and lipoprotein metabolism that characterize the dyslipidemia of insulin resistance and type 2 diabetes mellitus. We also examine the relevance of the new AHA/ADA treatment guidelines to dyslipidemic individuals. RECENT
findingsIn this review, we provide an update on the pathophysiology of diabetic dyslipidemia, including the role of several apolipoproteins such as apoC-III. We also point to new studies and new agents for the treatment of individuals with type 2 diabetes mellitus who need lipid therapies. Type 2 diabetes mellitus causes cardiovascular disease via several pathways, including dyslipidemia characterized by increased plasma levels of apoB-lipoproteins and triglycerides, and low plasma concentrations of HDL cholesterol. Treatments to normalize the dyslipidemia and reduce the risk for cardiovascular events include the following: lifestyle and medication, particularly statins, and if necessary, ezetimibe, to significantly lower LDL cholesterol. Other treatments, more focused on triglycerides and HDL cholesterol, are less well supported by randomized clinical trials and should be used on an individual basis. Newer agents, particularly the PCSK9 inhibitors, show a great promise for even greater lowering of LDL cholesterol, but we await the results of ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.